Episoder
-
Modern humans are stressed creatures: overloaded schedules, constantly “on-call,” and social media haunting us into the late night.
Part of this stress is maladaptive responses that date back to human history when stressors were about life and death and not about writing emails and making phone calls. A key player in those ancient responses is cortisol, a stress hormone that interacts with many biological functions, from heart rate to glucose metabolism, to inflammation and immune responses, as well as sleep and cognition.
But is cortisol - as the social media proponents of the so-called cortisol detox make us believe - really the root of all our problems, and would it be desirable to get rid of stress altogether?
Tune into episode 29 of We're Doomed, We're Saved and learn about the biological basis and myths surrounding stress and cortisol.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
Kenny Eliason
Further reading:
1. https://www.nature.com/articles/s41380-021-01224-9
2. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1085950/full
3. https://www.mdpi.com/2073-4409/12/23/2726
4. https://pubmed.ncbi.nlm.nih.gov/34290370/
5. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2018.00127/full
6. https://www.nature.com/articles/s44220-023-00016-0
7. https://www.geo.de/wissen/gesundheit/cortisol-reduzieren--was-steckt-hinter-dem-gesundheitstrend--34986216.html -
Science can be complex and difficult to grasp, yet public understanding is crucial for navigating issues like disease risk, climate change, and pandemics. Clear, engaging science communication can help prevent misinformation and conspiracy theories, offering facts in place of myths. But how can we make science more digestible and appealing?
Counterintuitively, it might be less facts and more emotions that can help to make science more appealing, more impactful – both when communicating to the public and to fellow scientists. In episode 28 of We’re doomed, We’re saved, Andreas Horchler and Louise von Stechow discuss strategies for scientific storytelling, drawing on principles that go back to ancient Greece and draw from modern brain science. Spoiler: It´s not as hard as it may look.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
FUJIFILM, X100F via Unsplash
Further reading:
Cron, Lisa: "Wired for story, The Writer's Guide to Using Brain Science to Hook Readers from the Very First Sentence" Clarkson Potter/Ten Speed, 2012
Gallo, Carmine: "Talk like Ted" Main Market Edition, 2022 -
Mangler du episoder?
-
In the expensive and failure-prone process of drug development, artificial intelligence (AI) can serve both as an efficiency tool and as a creativity tool. Increased efficiency means shorter timelines, reduced investment, and earlier insights into success or failure. This can lead to more opportunities to bring new drugs to patients. Increased creativity means exploring new areas in drug discovery and development, such as identifying new patterns in targets, drug molecules, and patient populations that may be unintelligible to the human eye. While we are witnessing the first tangible milestones of AI in drug development, the hype in the field can lead to inflated expectations of its benefits.
To assess the true potential of the technology, we must also recognize its challenges, such as the algorithms' "black box" nature, their propensity for hallucination, and data bias. Only by being transparent about both the potential and the limitations of AI can we increase the trust of drug developers—and most importantly, our customers: patients.
Listen to episode 27 of We’re Doomed, We’re Saved to learn more about the potential of AI for pharma and biotech.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
ej-strat-VjWi56AWQ9k-unsplashvia Unsplash
References:
1. https://www.nature.com/articles/s41591-023-02361-0
2. https://www.wired.com/2016/03/two-moves-alphago-lee-sedol-redefined-future/
3. https://www.nature.com/articles/d41586-023-02896-9
4. https://www.nature.com/articles/d43747-024-00084-w
5. https://www.nature.com/articles/d43747-024-00084-w
6. https://www.nature.com/articles/d43747-024-00084-w
7. https://endpts.com/the-endpoints-slack-interview-siddhartha-mukherjee-on-the-doctor-writer-worldview-ai-and-the-future-of-cancer/
8. https://endpts.com/the-endpoints-slack-interview-siddhartha-mukherjee-on-the-doctor-writer-worldview-ai-and-the-future-of-cancer/
9. https://hbr.org/2024/05/ais-trust-problem -
How will the medicine of the future look? Healthcare and medicine are on the verge of transformative change, driven by new technologies such as artificial intelligence, telemedicine, and wearable devices. Alongside the technologization and virtualization of medicine, there is a shift from reactive "fix the broken" approaches to preventative strategies and from one-size-fits-all treatments to personalized medicine.
In this future, human healthcare professionals and machines will work hand-in-hand to deliver the best possible care, with empowered patients acting as equal decision-makers who understand and access their own healthcare data. However, a darker scenario could see medicine becoming fully industrialized and dehumanized.
In episode 26 of We’re Doomed, We’re Saved, Andreas Horchler and Louise von Stechow outline the key trends shaping the future of medicine and discuss the opportunities and risks that accompany these developments.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
alexander-sinn-KgLtFCgfC28-unsplash via Unsplash
References:
https://www.nature.com/articles/s41591-019-0693-y?fbclid=IwZXh0bgNhZW0CMTAAAR0RAb4UU5v5896AQfVNYfdCpLi80iN7JwoZux55ffxyI9W7TMsqVPakS3M_aem_49GYkWynL_l8fmMWXq_Xlg
https://www.zukunftsinstitut.de/zukunftsthemen/megatrend-gesundheit
https://www.nature.com/articles/s41591-024-03097-1#Sec9
https://www.nature.com/articles/s41591-023-02700-1
https://ai.nejm.org/doi/full/10.1056/AIcs2300145
https://www.nature.com/articles/s41599-022-01451-7
https://www.nejm.org/doi/10.1056/NEJMra2215899?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
https://www.imperial.ac.uk/news/167866/information-handling-some-health-apps-secure/
https://journals.sagepub.com/doi/full/10.1177/1357633X211022907
https://www.mckinsey.com/industries/life-sciences/our-insights/germanys-e-health-infrastructure-strengthens-but-digital-uptake-is-lagging
https://www.mckinsey.com/industries/life-sciences/our-insights/german-e-health-offerings-expand-but-adoption-remains-uneven
https://empeek.com/insights/everything-about-telemedicine-statistics-usage-trends/
https://blogs.deloitte.co.uk/health/2023/11/the-future-of-health-in-europe-digital-equitable-sustainable.html
https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care/deloitte-uk-shaping-the-future-of-european-healthcare.pdf
https://www.nature.com/articles/s41569-021-00522-7
https://web-assets.bcg.com/1e/74/5d14d48346bcb56a79c6e7e7ba0f/bcg-the-future-of-digital-health-2024-jan-2024-1.pdf -
Some 36 months after the release of ChatGPT, the verdict is still out on the role that large language models (LLMs) will play in biotech, pharma, and medicine. On paper, the range of tasks that LLMs can perform in biomedical research and healthcare is vast—excavating relevant information for drug discovery from mountains of scientific literature, designing novel proteins, transcribing doctors' notes, aiding diagnostic decision-making, and acting as patient-facing chatbots.
But given the models’ propensity to hallucinate, we need to define how much error we can tolerate for different LLM use cases in the biomedical fields and create evaluation frameworks that allow us to apply the models confidently. In some cases, it might turn out that the time spent for human supervision of the model will outweigh the efficiency gain.
In episode 25 of We’re doomed we’re saved we talk to idalab founder and mathematician, Paul von Bünau we discuss the promise and challenges of LLMs in the biomedical field and ask the question if we can ever stop them from hallucinating.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
jo-coenen-studio-dries-2-6-yST9mzlMVLQ via Unsplash
References:
Excavating scientific literature
1. https://www.nature.com/articles/s41587-023-01788-7
2. https://idalab.de/insights/how-large-language-models-excavate-crucial-information-to-scale-drug-discovery
3. https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(23)00222-6#secsectitle0015
Unburdening Healthcare
1. https://www.nature.com/articles/s41591-023-02700-1
2. https://medium.com/mantisnlp/applications-of-llms-in-patient-care-83e07548dbb1#:~:text=Applications%20of%20LLMs%20in%20Patient%20Care%201%201.,6%206.%20Personalized%20Health%20Plans%20and%20Coaching%20
3. https://www.nature.com/articles/s41591-023-02700-1
4. https://arxiv.org/pdf/2303.16416
5. https://www.nature.com/articles/s41467-024-46411-8
6. https://link.springer.com/article/10.1007/s00330-023-10213-1
7. https://link.springer.com/article/10.1007/s00330-023-10213-1
8. https://link.springer.com/article/10.1007/s00330-023-10213-1
9. https://www.nature.com/articles/s41591-024-03097-1#Sec9
Reading molecular language
1. https://academic.oup.com/bioinformatics/article/36/4/1234/5566506
2. https://arxiv.org/abs/2106.03598
3. https://resources.nvidia.com/en-us-hc-biopharma/hc-solution-overview-5
4. https://www.nature.com/articles/s41592-024-02201-0#author-information
5. https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engineering-and-biosecurity-301912283.html
6. https://www.nature.com/articles/s41598-024-61124-0
7. https://www.nature.com/articles/s41587-022-01618-2
8. https://www.biopharmatrend.com/post/835-14-companies-pioneering-ai-foundation-models-in-pharma-and-biotech/
9. https://www.biorxiv.org/content/10.1101/2023.01.11.523679v1
10. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-024-05847-x
11. https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-024-05847-x
12. https://arxiv.org/abs/2403.04197
13. https://arxiv.org/abs/2311.07621 -
Rare or orphan diseases affect only a small percentage of the population and often lack effective treatments. While rare individually, in total, more than 350 million people worldwide live with rare diseases. Many of these are very hard to diagnose, let alone cure, and the rarity of patients challenges the development of novel treatments.
To make the development of drugs for rare diseases more efficient and successful, artificial intelligence could be an important ally not only for drug makers but also for patients.
In episode 24 of "We’re Doomed, We’re Saved," Andreas Horchler and Louise von Stechow discuss the benefits and challenges of using AI for drug development in rare diseases.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
Geranimo via Unsplash -
When we think about revolutions, we think of systemic changes in politics, economics, and lifestyles. Revolutions transform how we live, work, interact, and communicate. In the past, political uprisings and new technologies, from the steam engine to the smartphone, have led to such transformative changes.
Now, a revolution driven by novel biotechnologies (gene editing, neuroprosthetics, synthetic biology, and artificial intelligence in biotech) has the potential to not only change the way we live but the very foundations of our lives – our biology.
But is the so-called biorevolution a real "scientific revolution"?
In the new episode of "We're Doomed, We're Saved," Andreas Horchler and Louise von Stechow look at the biorevolution from different angles, examining its transformative potential and comparing it to revolutions that came before.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
Acton Crawford via Unsplash -
Polygenic risk scores (PRS), put simply, look at gene variants across the human genome in order to determine an individual's risk of getting a disease, from different types of cancer to type II diabetes. PRS could complement current risk prediction models and lead to a more accurate risk prediction. However, for PRS to become a useful clinical instrument, transparent ways to assess their performance and careful communication of disease risks to individuals are key.
In episode 22 of We’re doomed we’re saved, Andreas Horchler and Louise von Stechow speak to two PRS researchers, who contributed to the international and interdisciplinary, EU-funded INTERVENE project.
Brooke Wolford, a Postdoctoral Fellow in the HUNT Center for Molecular and Clinical Epidemiology at the Norwegian University of Science and Technology and Kristi Läll, a researcher in statistical genetics at Institute of Genomics, University of Tartu, share their expertise on PRSs and discuss the potential of PRSs in the clinic and pinpoint strategies for addressing biases in PRS.
Learn more about IINTERVENE here:
INTERVENE is coordinated by the Institute for Molecular Medicine Finland at the University of Helsinki. The project includes 17 research and other organizations from 10 countries. Learn more about INTERVENE here:
https://www.interveneproject.eu/
You can read more about Brooke at
https://bnwolford.github.io/
Also check out recent publications here:
https://www.medrxiv.org/content/10.1101/2023.11.20.23298215v1
https://www.medrxiv.org/content/10.1101/2023.06.12.23291186v1
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
scientific communication: https://science-tales.com/
Podcasts: https://www.podcon.de/
Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image:
Acton Crawford via Unsplash -
Aging is a dynamic process characterized by the accumulation of cell damage, tissue, and organ degeneration, and diminished function. This process of decline appears to be an inevitable aspect of human existence. In recent years, however, advancements in scientific understanding of aging bring us closer to extending the human lifespan.
With their guests, Dr. Jürgen Reess and Prof. Hartmut Geiger, founders of Moglingbio, Louise von Stechow and Andreas Horchler explore the complex science underlying the process of aging and the challenges faced by the budding longevity industry. They talk about the potential for rejuvenating aged cells in human tissues and the ethical considerations of extending the human lifespan.
Content and Editing:
Louise von Stechow and Andreas Horchler
Disclaimer:
Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Image:
Marcelo Leal via Unsplash
References:
Theories and Hallmarks of Aging
1. https://www.afar.org/imported/AFAR_INFOAGING_GUIDE_THEORIES_OF_AGING_2016.pdf
2. https://www.nature.com/scitable/knowledge/library/the-evolution-of-aging-23651151/
3. https://www.nature.com/articles/s41576-022-00513-5
4. https://www.cell.com/fulltext/S0092-8674(13)00645-4
5. https://www.nature.com/articles/s43587-022-00335-4
6. https://www.nytimes.com/2021/04/27/magazine/global-life-span.html
Life-prolonging treatments and Cell Rejuvenation
1. https://www.science.org/content/article/feature-man-who-wants-beat-back-aging
2. https://www.nature.com/articles/s43587-023-00416-y
3. https://www.nature.com/articles/s41586-021-04282-9
4. https://dogagingproject.org/triad
5. https://www.dvcstem.com/post/anti-aging-stem-cells
6. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117
7. https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
8. https://pubmed.ncbi.nlm.nih.gov/27286740/
9. https://www.nature.com/articles/s41392-023-01343-5
10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023768/
11. https://pubmed.ncbi.nlm.nih.gov/35859206/
12. https://www.nature.com/articles/s41536-022-00275-y
13. https://www.nature.com/articles/s43587-023-00528-5
14. https://www.nature.com/articles/s41591-022-01923-y
15. https://www.nature.com/articles/s43587-023-00373-6
The longevity industry
1. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/longevity-science.html
2. https://www.forbes.com/sites/forbestechcouncil/2021/05/03/will-you-live-to-200-five-levels-of-breakthroughs-in-longevity-research-you-must-know-about/
3. https://www.theguardian.com/books/2022/may/02/could-we-make-aging-a-thing-of-the-past
4. https://longevity.technology/news/unity-cuts-lead-program-after-clinical-trial-fail/
5. https://longevity.technology/news/global-longevity-investment-hit-5-2-billion-in-2022/
6. https://www.nature.com/articles/d41587-022-00002-4
7. https://www.forbes.com/sites/alexzhavoronkov/2023/09/16/what-is-a-longevity-biotechnology-company/?sh=4d4ac9a7702a
8. https://venturebeat.com/business/the-brains-behind-calico-bill-maris-of-google-ventures/
9. https://spannr.com/articles/longevity-industry-introduction#:~:text=What%20is%20the%20longevity%20industry%3F%20The%20longevity%20industry,promote%20healthy%20aging%20and%20improve%20quality%20of%20life.
10. https://edition.cnn.com/2013/10/03/tech/innovation/google-calico-aging-death/index.html -
Women make up about half of humanity. Yet, the medical community and the pharmaceutical and biotech industries have long adopted an androcentric view of disease biology and healthcare needs, perceiving women as a specialized or atypical demographic—outliers.
In episode 20 of "We're Doomed, We're Saved," we talk to two biotech experts, Catenion's Dr. Ana Rita Da Costa and Dr. Pascal Joly, to discuss how the biotech industry and healthcare community slowly, but steadily, change and adapt to the needs of half of their customers: women. -
RNA, one of the oldest and most versatile biomolecules, has recently entered the therapeutic arena. While for many observers the success of mRNA vaccines seemed to come out of the blue, its build on the fundament of research that has large gone ignored.
Now mRNA therapeutics are enjoying the limelight of great economic success for companies like BioNTech / Pfizer and Moderna, and the awarding of the 2023 Nobel Prize to two mRNA researchers. But with the fame also comes a huge public backlash of anti-vaxxers who fear the perceived novelty of mRNAs.
In the 19th episode of We're doomed, we're saved Louise von Stechow and Andreas Horchler talk with their guest, mRNA researcher Lucia Lapazio who has known the field before and after the hype. -
In principle the solution to the problem of overweight should be very easy:eat less and exercise more.But anyone who’s ever tried to lose weight – so probably almost anyone – will be able to testify that things are not as simple. So now Ozempic enters the scene, a diabetes drug that looks like a gamechanger in the big business of weight loss.
In episode 18 of We're doomed we're saved, Andreas Horchler and Louise von Stechow discuss the history of weight loss pills and the medical and cultural reasons why we (think we) need to be thin. -
Gene editing technology allows humans, for the first time, to change the code of life with a precise editing system offering the potential for curing genetic diseases. The gene editing field is moving with impressive speed: after the seminal paper on the technology was published in 2012, the Nobel Prize awarded for the technology in 2020, and the first therapy approved for treatment of blood diseases in 2023.
In this episode of We’re doomed, we’re saved Andreas Horchler and Louise von Stechow, discuss the tremendous potential of the technology, but also its darker side – the high cost of the therapeutic applications and the potential for augmenting, altering, and redesigning human genomes. -
Synthetic biology - the artificial creation of biological molecules, cells, and even organisms - has the potential to revolutionize biotechnology and agriculture, allowing for the creation of novel biomaterials and fuels, opening new opportunities for DNA-based information storage and computation, and even aiding in the exploration and colonization of space. The first synthetic bacterium was created about ten years ago, and since then, the technologies supporting synthetic biology have become faster, cheaper, and more innovative. With the assistance of artificial intelligence, synthetic biology could unlock vast potential, recognized by various industries. Synthetic biology could also enable bad actors to create harmful microbes.
-
In our data-heavy age, data becomes a treasure, a currency, a valuable good. This is true especially for the biotech and pharmaceutical industries, where data can inform the development of novel drugs. But should own biomedical data – and where should the lines between privacy and patient benefit be drawn?
In the new episode of We’re doomed, we’re saved, Andreas Horchler and Louise von Stechow discuss new strategies of data sharing and ownership in biomedicine and pharma. -
The rapid spread of humans is causing many species to disappear off the face of the earth – in a so-called mass extinction. Some scientists are trying to reverse this process, by bringing back extinct species, such as the Dodo, the Passenger Pigeon, or the Wolly Mammoth.
In the 14th episode of We’re doomed, we’re saved Andreas Horchler and Louise von Stechow discuss the breeding procedures and genetic engineering techniques that might be used for brining back extinct animals. We also discuss the ethical implications from resource waste to animal welfare – and what it might mean to be the first and the last member of a (de)extinct species. -
Ein Jahr We're doomed we're saved - seiten einem Jahr sprechen Andreas Horchler und Louise von Stechow über die Themen der Biorevolution. Wir haben über Anitbiotikaresistenzen, Biowaffen, Gentherapien, Neuroprothesen und AI gesprochen. Wir hatten spannende Gäste, wie den Mathematiker und idalab Gründer Paul von Bünau, und den Forschungs- und Entwicklungschef von Sanofi Adventis Deutschland mit denen wir über die Rolle neuer Technologien wie AI für die Medikamentenentwicklung gesprochen haben.
In dieser Folge lassen wir die erste Staffel Revue passieren und machen "A big announcment". Dies wird unsere vorerst letzte Deutsche Episode sein - in der neuen Staffel, ab September, werden wir uns auf Englisch unterhalten. -
Follow the money, folge dem Geld, ist eine alte Weisheit wenn man den Kern einer Angelegenheit verstehen will.
In der 12. Folge von We're doomed we're saved folgen wir diesem Weg zu den Geldquellen der Biomedizinischen Forschung, zu Regierungszuschüssen, großen Pharmaunternehmen und privaten Stiftungen, wie der Bill und Melinda Gates Foundation, die ganze Forschungszweige quasi im Alleingang finanziert. Solche privaten Geldgeber haben besonders in den USA einen großen Einfluss auf die Forschungslandschaft, obwohl ihre Auswahlkriterien und Transparenz umstritten sind und die Verbindung von Wissenschaftlern und reichen Technokraten das Vertrauen in die Wissenschaft verringern kann.
Von und mit Andreas Horchler und Louise von Stechow -
Wie werden neue Technologien, wie die künstliche Intelligenz die Pharmaindustrie beeinflussen? Welche neuen Modelle werden die Blockbuster der Vergangenheit ablösen?
In dieser Folge sprechen wir mit unserem Gast Professor Jochen Maas, Geschäftsführer Forschung & Entwicklung der Sanofi-Aventis, Deutschland GMBH über die Zukunft der Pharmaindustrie -
Biohacker experimentieren an sich selbst, führen genetische Modifikationen durch, implantieren Mikrochips und testen neue Medikamente. Dabei bewegen sie die Wissenschaft aus den Elfenbeintürmen der Universitäten hin zu privaten Laboren, Küchen und Garagen. Dies verspricht größere Chancengleichheit und neue Möglichkeiten für Innovationen in der Wissenschaft, birgt jedoch auch die Gefahr einer mangelnden Regulierung mit unvorhersehbaren Konsequenzen.
In der neuen Folge von We’re doomed we’re saved besprechen Andreas Horchler und Louise von Stechow die Ziele und Methoden der Biohacker und stellen die Frage ob sie eine Chance ohne eine Gefahr darstellen. - Se mer
